Progress in the Pathogenesis of Diabetic Encephalopathy: The Key Role of Neuroinflammation
Authors:
- 18 September 2024
- journal article
- review article
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 40 (6) , e3841
Abstract
Diabetic encephalopathy (DE) is a severe complication that occurs in the central nervous system (CNS) and leads to cognitive impairment. DE involves various pathophysiological processes, and its pathogenesis is still unclear. This review summarised current research on the pathogenesis of diabetic encephalopathy, which involves neuroinflammation, oxidative stress, iron homoeostasis, blood‐brain barrier disruption, altered gut microbiota, insulin resistance, etc. Among these pathological mechanisms, neuroinflammation has been focused on. This paper summarises some of the molecular mechanisms involved in neuroinflammation, including the Mammalian Target of Rapamycin (mTOR), Lipocalin‐2 (LCN‐2), Pyroptosis, Advanced Glycosylation End Products (AGEs), and some common pro‐inflammatory factors. In addition, we discuss recent advances in the study of potential therapeutic targets for the treatment of DE against neuroinflammation. The current research on the pathogenesis of DE is progressing slowly, and more research is needed in the future. Further study of neuroinflammation as a mechanism is conducive to the discovery of more effective treatments for DE in the future.Keywords
This publication has 310 references indexed in Scilit:
- The impact of diabetes on cognitive impairment and its progression to dementiaAlzheimer's & Dementia, 2021
- Emerging insights into molecular mechanisms underlying pyroptosis and functions of inflammasomes in diseasesJournal of Cellular Physiology, 2019
- Endoplasmic reticulum stress and NLRP3 inflammasome: Crosstalk in cardiovascular and metabolic disordersJournal of Cellular Physiology, 2019
- Microbiome, inflammation, epigenetic alterations, and mental diseasesAmerican Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2017
- Astrocyte‐derived lipocalin‐2 mediates hippocampal damage and cognitive deficits in experimental models of vascular dementiaGlia, 2017
- Emerging Targets for Therapeutic Development in Diabetes and Its Complications: The RAGE Signaling PathwayClinical Pharmacology & Therapeutics, 2015
- Mechanism and clinical evidence of lipocalin‐2 and adipocyte fatty acid‐binding protein linking obesity and atherosclerosisDiabetes/Metabolism Research and Reviews, 2013
- Lipocalin 2 is a novel immune mediator of experimental autoimmune encephalomyelitis pathogenesis and is modulated in multiple sclerosisGlia, 2012
- Diet‐induced insulin resistance impairs hippocampal synaptic plasticity and cognition in middle‐aged ratsHippocampus, 2008
- High glucose stimulates GRO secretion from rat microglia via ROS, PKC, and NF‐κB pathwaysJournal of Neuroscience Research, 2007